Nerissa Kreher
Nerissa Kreher's purchase track record
Nerissa Kreher has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/13/2025 | RZLT | $10K | +83.1% | -57.1% | +14.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Rezolute Q4 EPS Misses Estimates, Reports Fiscal 2026 Results. Rezolute reported fourth-quarter and full-year fiscal 2026 financial results, with an EPS of $(0.20) missing the expected $(0.15). The company also provided a business update alongside these figures. The stock is currently trading near its support level, reflecting the market's reaction to the earnings miss.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
Transaction History
| XERS | ▲ Buy | Grant | 33,582 | $0 | 7/1/2026 | View on chart |
| RZLT | ▲ Buy | Grant | 21,000 | $0 | 11/19/2025 | View on chart |
| RZLT | ▲ Buy | Open Market | 3,076 | $10K | 6/13/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 9,000 | $0 | 6/10/2025 | View on chart |
| RZLT | ▲ Buy | Grant | 25,500 | $0 | 2/16/2025 | View on chart |
| TRDA | ▼ Sell | Open Market | 871 | $12K | 9/6/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 21 | $294 | 9/6/2023 | View on chart |
| TRDA | ▼ Sell | Tax Withholding | 401 | $6K | 9/5/2023 | View on chart |
| TRDA | ▲ Buy | Grant | 14,200 | $0 | 9/1/2023 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 6,898 | $14K | 8/4/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 6,898 | $98K | 8/4/2023 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 9,464 | $20K | 8/3/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 9,464 | $140K | 8/3/2023 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 10,348 | $22K | 8/2/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 9,280 | $140K | 8/2/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 1,000 | $16K | 8/2/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 68 | $1K | 8/2/2023 | View on chart |
| TRDA | ▼ Sell | Tax Withholding | 945 | $11K | 3/2/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 1,477 | $15K | 3/2/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 164 | $2K | 3/2/2023 | View on chart |
| TRDA | ▲ Buy | Grant | 28,400 | $0 | 3/1/2023 | View on chart |
| TRDA | ▼ Sell | Open Market | 5,200 | $70K | 12/30/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 4,960 | $10K | 10/26/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 643 | $14K | 10/26/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 4,317 | $95K | 10/26/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 8,040 | $17K | 10/25/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 4,942 | $101K | 10/25/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 2,998 | $64K | 10/25/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 100 | $2K | 10/25/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 3,122 | $7K | 9/28/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 3,122 | $48K | 9/28/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 2,403 | $5K | 9/27/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 2,403 | $37K | 9/27/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 3,068 | $6K | 9/26/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 2,768 | $42K | 9/26/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 300 | $5K | 9/26/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 939 | $2K | 9/23/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 939 | $14K | 9/23/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 3,341 | $7K | 9/21/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 3,341 | $50K | 9/21/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 106 | $223 | 9/15/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 106 | $2K | 9/15/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 800 | $2K | 9/9/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 800 | $12K | 9/9/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 1,221 | $3K | 9/8/2022 | View on chart |
| TRDA | ▼ Sell | Open Market | 1,221 | $18K | 9/8/2022 | View on chart |
| TRDA | ▲ Buy | Grant | 5,172 | $0 | 9/1/2022 | View on chart |
| TRDA | ▲ Buy | Grant | 10,344 | $0 | 3/1/2022 | View on chart |
| TRDA | ▲ Buy | Option Exercise | 5,200 | $11K | 12/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit
Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.